GlobeStar Therapeutics Corp: 10-K filed 2015-01-27
What GlobeStar Therapeutics Corp reported in its annual report filed 2015-01-27 (fiscal FY 2014): 23 published measures, 47 facts as tagged in accession 0001161697-15-000043.
This filing
- Form
- 10-K (annual report)
- Filed
- 2015-01-27
- Fiscal period
- fiscal FY 2014
- Accession
- 0001161697-15-000043 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 477,603 | USD | |
| At 2013-09-30 | 462,558 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 582,038 | USD | |
| At 2013-09-30 | 217,276 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | -104,435 | USD | |
| At 2013-09-30 | 245,282 | USD | |
| At 2012-09-30 | -106,134 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 1,211 | USD | |
| At 2013-09-30 | 127,748 | USD | |
| At 2012-09-30 | 1,359 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -1,245,170 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -946,111 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -311,008 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -429,524 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 97,252 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 57,361 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 324,285 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 718,999 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -139,814 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -163,086 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | -3,356,775 | USD | |
| At 2013-09-30 | -2,111,605 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -457,567 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -645,198 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 29,262 | USD | |
| At 2013-09-30 | 138,206 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 787,603 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 300,913 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 560,760 | USD | |
| At 2013-09-30 | 121,058 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 15,891 | USD | |
| At 2013-09-30 | 10,458 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 52,047 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 147,427 | USD | 365 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 3,232,399 | USD | |
| At 2013-09-30 | 2,355,801 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 17,379 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -1,227,791 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -946,111 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 502,772 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 555,132 | USD | 365 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 30,209 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 60,671 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | -787,603 | USD | 365 |
| 2012-10-01 to 2013-09-30 | -300,913 | USD | 365 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-09-30 | 5,433 | USD | 365 |
| 2012-10-01 to 2013-09-30 | 10,458 | USD | 365 |
Inspect the source
- Entity
- GlobeStar Therapeutics Corp / CIK 0001502152
- Captured
- 2026-09-21T17:19:31.788Z
- SEC response SHA-256
6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))